FDA Expands Approval for Enhertu®
On December 15, 2025, the FDA expanded approval for fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) in combination with pertuzumab (Perjeta®) as...
Read More PAST ARTICLES
2025
2024
2023
2020
SEARCH OUR SITE
for past articles or specific information.